Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor in Stable Heart Failure With Reduced Ejection Fraction
NCT07695090Phase 2Recruiting
- Sponsor
- Qanatpharma
- Start
- Jul 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Lumacaftor with Placebo (2 arms). Primary endpoint: Cerebral Blood Flow at 1 month. Started Jul 2026; status: recruiting.
02
Drugs
lumacaftor
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07695090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695090.